Search

Displaying results 2451 - 2460 of 10000 in total
  1. Drug

    RGX-501

    go.drugbank.com/drugs/DB17639
    Investigational

    RGX-501 is an adeno-associated virus vector 8 (AAV8)-mediated gene therapy that delivers a functional copy of the human low-density lipoprotein receptor (LDLR) gene to liver cells.

  2. Drug

    Prednisolone phosphate

    go.drugbank.com/drugs/DB14631
    ApprovedInvestigationalVet approved

    Prednisolone phosphate is a glucocorticoid similar to cortisol used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects. Prednisolone phosphate was granted FDA Approval on 19 December 1973.

    Mixtures: OFTALETYC® NF
  3. Drug

    Polysilicone-15

    go.drugbank.com/drugs/DB11271
    Approved

    Polysilicone-15 is a silicone based UVB absorber . The compound is a colorless to pale yellow viscous liquid which is soluble in organic solvents of medium polarity and insoluble in water . It is the first polymeric UVB filer consisting ...

  4. Drug

    Sinapultide

    go.drugbank.com/drugs/DB11332
    ApprovedWithdrawn

    This large disadvantage was overcome with animal-derived surfactant products which contain specific proteins but are limited, but must be derived from animal sources. … Surfactant replacement therapy has been commonly used to prevent and treat RDS in these newborns and is now a standard of care.

  5. Drug

    Geraniol

    go.drugbank.com/drugs/DB14183
    Approved

    These pharmacologic effects are clinically important as geraniol is classified as generally-recognized-as-safe (GRAS) by the Flavor and Extract Manufacturers Association (FEMA) and the Food and Drug Administration … It is emitted from the flowers of many species of plant and is commonly used by the food, fragrance, and cosmetic industry[L3333].

  6. Drug

    Aprocitentan

    go.drugbank.com/drugs/DB15059
    ApprovedInvestigational

    [A263386,L50261] Aprocitentan was approved by the FDA in March 2024 for the treatment of hypertension in patients inadequately controlled with standard therapy.

  7. Drug

    Bromfenac

    go.drugbank.com/drugs/DB00963
    ApprovedWithdrawn

    Non-ophthalmic formulations of bromfenac were withdrawn in the US in 1998 due to cases of severe liver toxicity.[L43942,T239]

    Categories: Anti-Inflammatory Agents, Non-Steroidal (Non-Selective), Analgesics, Non-Narcotic
  8. Drug

    Inositol nicotinate

    go.drugbank.com/drugs/DB08949
    ApprovedWithdrawn

    Inositol nicotinate, also known as Inositol hexaniacinate/hexanicotinate or "no-flush niacin", is a niacin ester and vasodilator. … It is associated with reduced flushing compared to other vasodilators by being broken down into the metabolites and inositol at a slower rate.

  9. Drug

    Cilostazol

    go.drugbank.com/drugs/DB01166
    ApprovedInvestigational

    It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both primary and secondary aggregation and reducing calcium-induced contractions.

  10. Drug

    mRNA-1010

    go.drugbank.com/drugs/DB22484
    Approved

    MFLUSIVA (influenza vaccine, mRNA), also known by its development code mRNA-1010, is a messenger RNA–based vaccine for active immunization against seasonal influenza.